Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

(2019) Musa Yilmaz et al.   Blood Cancer Journal

Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response

(2019) Hong Yuen Wong et al.   Frontiers in Oncology

Next generation sequencing in diagnosis and MRD assessment of AML

(2019) Ross L. Levine et al.   HAEMATOLOGICA

Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity

(2019) Peter van Galen et al.   CELL

NGS‐Defined Minimal Residual Disease Before Stem Cell Transplantation Predicts Acute Myeloid Leukemia Relapse

(2019) Richard D. Press et al.   AMERICAN JOURNAL OF HEMATOLOGY

Evolutionary trajectory of leukemic clones and its clinical implications

(2019) Amos Tuval et al.   HAEMATOLOGICA

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

(2019) Adriano Venditti et al.   BLOOD

Clonal evolution of acute myeloid leukemia from diagnosis to relapse

(2019) Sebastian Vosberg et al.   GENES CHROMOSOMES & CANCER

Clonal hematopoiesis in human aging and disease

(2019) Siddhartha Jaiswal et al.   SCIENCE

Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1 -Mutated AML

(2018) Yi Zhou et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group

(2018) Jason Aynardi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

(2018) Yann Ferret et al.   HAEMATOLOGICA

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia

(2018) Kiyomi Morita et al.   JOURNAL OF CLINICAL ONCOLOGY

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia

(2018) Maja Rothenberg-Thurley et al.   LEUKEMIA

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

(2018) Mojca Jongen-Lavrencic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia

(2018) Hidemasa Matsuo et al.   PEDIATRICS INTERNATIONAL

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

(2018) Yann Ferret et al.   HAEMATOLOGICA

Is it time to routinely incorporate MRD into practice?

(2018) Farhad Ravandi   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Identifying patients with genetic predisposition to acute myeloid leukemia

(2018) Ellyn Obrochta et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Measurable residual disease (MRD) monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

(2018) Felicitas Thol et al.   BLOOD

IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?

(2018) Lucie Petrova et al.   CLINICAL BIOCHEMISTRY

Persistent IDH1/2 mutation in remission can predict relapse in patients with acute myeloid leukemia

(2018) Chi Young Ok et al.   HAEMATOLOGICA

European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation

(2018) Nicole Engel et al.   LEUKEMIA

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

(2018) Uwe Platzbecker et al.   LANCET ONCOLOGY

Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia

(2017) Pierre Hirsch et al.   HAEMATOLOGICA

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

(2017) Uwe Platzbecker et al.   JOURNAL OF CLINICAL ONCOLOGY

Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML

(2017) S Herold et al.   LEUKEMIA

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia

(2017) V I Gaidzik et al.   LEUKEMIA

Tracing the origins of relapse in acute myeloid leukaemia to stem cells

(2017) Liran I. Shlush et al.   NATURE

Measurement of Residual Disease in Acute Myeloid Leukemia

(2017) Rahul S. Vedula et al.   Current Hematologic Malignancy Reports

Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia

(2017) Pierre Hirsch et al.   HAEMATOLOGICA

Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy

(2016) Katarzyna Rojek et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy

(2016) G L Uy et al.   LEUKEMIA

Assessment of Minimal Residual Disease in Standard-Risk AML

(2016) Adam Ivey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Significance of Mixed-Lineage Leukemia (MLL) Gene Detected by Real-Time Fluorescence Quantitative PCR Assay in Acute Myeloid Leukemia

(2016) Sai Huang et al.   MEDICAL SCIENCE MONITOR

The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia

(2015) Juan Ouyang et al.   AMERICAN JOURNAL OF HEMATOLOGY

Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression

(2015) C. A. Cargo et al.   BLOOD

Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML

(2015) T. N. Wong et al.   BLOOD

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

(2015) D. P. Steensma et al.   BLOOD

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial

(2015) C. Willekens et al.   HAEMATOLOGICA

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia

(2015) Jeffery M. Klco et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2015) Mia Y. Platt et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone

(2015) C N Hahn et al.   LEUKEMIA

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

(2015) Houria Debarri et al.   Oncotarget

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial

(2015) C. Willekens et al.   HAEMATOLOGICA

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

(2014) R. C. Lindsley et al.   BLOOD

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

(2014) Liran I. Shlush et al.   NATURE

Age-related mutations associated with clonal hematopoietic expansion and malignancies

(2014) Mingchao Xie et al.   NATURE MEDICINE

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic impact ofRASmutations in patients with myelodysplastic syndrome

(2013) Aref Al-Kali et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia

(2013) J. Kronke et al.   BLOOD

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease

(2013) A Kohlmann et al.   LEUKEMIA

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

(2012) J. A. L. Yin et al.   BLOOD

The Origin and Evolution of Mutations in Acute Myeloid Leukemia

(2012) John S. Welch et al.   CELL

Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia

(2012) Hiroto Inaba et al.   JOURNAL OF CLINICAL ONCOLOGY

Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype

(2011) Torsten Haferlach et al.   LEUKEMIA RESEARCH

RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant

(2010) C. Ricci et al.   CLINICAL CANCER RESEARCH